iBio (NASDAQ:IBIO - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.
A number of other equities analysts also recently weighed in on IBIO. HC Wainwright initiated coverage on iBio in a research report on Thursday, September 17th. They set a "buy" rating and a $7.00 price target for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of iBio in a report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $6.00.
Read Our Latest Research Report on IBIO
iBio Stock Performance
Shares of iBio stock opened at $0.73 on Friday. The stock's 50-day moving average is $0.98 and its 200-day moving average is $1.63. iBio has a one year low of $0.69 and a one year high of $3.82.
iBio (NASDAQ:IBIO - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts expect that iBio will post -0.35 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Affinity Asset Advisors LLC increased its position in shares of iBio by 51.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,107,200 shares of the company's stock worth $5,904,000 after purchasing an additional 1,050,000 shares during the last quarter. ADAR1 Capital Management LLC raised its stake in shares of iBio by 15.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company's stock worth $893,000 after purchasing an additional 64,347 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of iBio in the 2nd quarter valued at approximately $873,000. Walleye Capital LLC boosted its holdings in shares of iBio by 95.9% in the 1st quarter. Walleye Capital LLC now owns 388,554 shares of the company's stock valued at $738,000 after buying an additional 190,179 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of iBio by 150.8% in the first quarter. Bank of America Corp DE now owns 290,413 shares of the company's stock valued at $552,000 after buying an additional 174,620 shares in the last quarter. 7.90% of the stock is owned by institutional investors and hedge funds.
iBio Company Profile
(
Get Free Report)
iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company's current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iBio wasn't on the list.
While iBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.